Skip to main content
×
Home
    • Aa
    • Aa

Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice

Abstract

Pharmacogenomic testing can be integrated into modern mental health practices to help select psychotropic drugs for individuals who have failed first-line evidence-based treatments. This can be done by the process of “equipoise”—namely, balancing the weight of all available evidence. That evidence now includes not only diagnosis-specific treatment guidelines and “personalized” patient information, such as an individual’s specific symptom profile, past response to medications, side effects, family history, and patient preference, but also “precision medicine,” which incorporates the ever-expanding base of pharmacogenomic evidence for how an individual’s own biomarkers alter the odds for that individual’s treatment response or treatment intolerance.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Psychiatric Pharmacogenomics: How to Integrate into Clinical Practice
      Available formats
      ×
Copyright
Footnotes
Hide All

Dr. Stahl was awarded the 2016 David A. Mrazek Award in Pharmacogenomics by the American Psychiatric Association, and this article is based on the David A. Mrazek Award Lecture, which Dr. Stahl delivered at the American Psychiatric Association meeting in Atlanta, Georgia, May 2016.

Footnotes
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1. SM Stahl . Personalized Medicine, pharmacogenomics and the practice of psychiatry: on the threshold of predict therapeutics in psychopharmacology? CNS Spectr. 2008; 13(2): 115118.

2. DA Mrazek . Psychiatric Pharmacogenomics. New York: Oxford University Press; 2010.

3. CA Bousman . Commercial pharmacogenomics-based decision support tools in psychiatry. Lancet Psychiatry. 2016; 3(6): 585590.

4. DL Braff , R Freedman . Clinically responsible genetic testing in neuropsychiatric patients: a bridge too far and too soon. Am J Psychiatry. 2008; 165(8): 952955.

5. AK Malhotra , GM Murphy , JL Kennedy . Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004; 161(5): 780796.

6. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome wide analysis. Lancet. 2013; 381(9875): 13711379.

7. FE Lotrich . The emerging potential of pharmacogenetics in psychiatry. Am J Psychiatry. 2012; 169(7): 681683.

8. CG Beevers , JE McGeary . Therapygenetics: moving towards personalized psychotherapy treatment. Trends Cogn Sci. 2012; 16(1): 1112.

9. M Falcone , RM Smith , MG Chenoweth , et al. Neuroimaging in psychiatric pharmacogenetics research: the promise and the pitfalls. Neurospsychopharmacology. 2013; 38(12): 23272337.

10. MA Varela , TC Roberts , MJA Wood . Epigenetics and ncRNAs in Brain Function and Disease: mechanisms and prospects for therapy. Neurotherapeutics. 2013; 10(4): 621631.

11. RH Perlis . Can single genes matter in a polygenic world? Biol Psychiatry. 2010; 68(9): 783784.

12. A Caspi , AR Hariri , A Holmes , R Uher , TE Moffitt . Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010; 167(5): 509527.

13. AB Niculescu , D Levey , H Le-Niculescu , E Niculescu , SM Kurian , D Salomon . Psychiatric mood biomarkers: avoiding jumping to premature negative or positive conclusions. Mol Psychiatry. 2015; 20(3): 286288.

14. SM Stahl . The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013; 18(2): 6568.

16. DA Morrissette , SM Stahl . Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014; 19(5): 439448.

17. SM Stahl , DA Morrissette , M Cummings , et al. California State Hospital Violence Assessment and Treatment (Cal-VAT) guideline. CNS Spectr. 2014; 19(5): 449465.

18. G Ruaño , BL Szarek , D Villagra , et al. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark Med. 2013; 7(3): 429439.

19. L Herbild , SE Andersen , T Werge , HB Rasmussen , G Jürgens . Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol. 2013; 113(4): 266272.

22. DK Hall-Flavin , JG Winner , JD Allen , et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012; 2: e172.

23. DK Hall-Flavin , JG Winner , JD Allen , et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013; 23(10): 535548.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 66
Total number of PDF views: 476 *
Loading metrics...

Abstract views

Total abstract views: 491 *
Loading metrics...

* Views captured on Cambridge Core between 7th February 2017 - 21st September 2017. This data will be updated every 24 hours.